Loading…

PO-210 Anticancer drug-induced senescence in glioblastoma cells is associated with changes in DNA repair capacity

IntroductionDespite extensive research, malignant glioma remains the most aggressive and fatal type of brain tumour. Following resection, therapy is based on radiation concomitant with the methylating agent temozolomide (TMZ), followed by adjuvant high dose TMZ treatment. The success of glioma thera...

Full description

Saved in:
Bibliographic Details
Published in:ESMO open 2018-07, Vol.3 (Suppl 2), p.A102-A102
Main Authors: Christmann, M, Aasland, D, Roos, W, Kaina, B, Tomicic, M
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b2575-539b778b60ed9cfe0d917f68f6eb78c9f6c1ce807b4d69cb44b6ec4cd87066093
cites
container_end_page A102
container_issue Suppl 2
container_start_page A102
container_title ESMO open
container_volume 3
creator Christmann, M
Aasland, D
Roos, W
Kaina, B
Tomicic, M
description IntroductionDespite extensive research, malignant glioma remains the most aggressive and fatal type of brain tumour. Following resection, therapy is based on radiation concomitant with the methylating agent temozolomide (TMZ), followed by adjuvant high dose TMZ treatment. The success of glioma therapy depends largely on the DNA repair capacity of the tumour cells, notable repair by MGMT, which confers resistance to TMZ. Beside DNA repair, other mechanisms involved in tumour protection may also play a role. These include the induction of a transient cell cycle arrest that provides time for repair and the induction of an irreversible cell cycle arrest in the form of senescence.Material and methodsMZ-induced senescence and repression of DNA repair was analysed in LN229, U87, LN308 and U138 glioblastoma cells using different techniques, including immunodetection, RT-qPCR, ChIP, Co-immunoprecipitation, ELISA, ß-Gal staining, C12FDG staining, AnexinV/PI staining, flow cytometry, pharmacological inhibition and si-RNA mediated knockdown.Results and discussionsWe show that following single and chronic TMZ exposure most glioma cells evade apoptosis and enter a senescent state. TMZ-induced senescence occurs in the G2/M phase of the cell cycle and is initiated by the ATR/CHK1-mediated degradation of CDC25c. It is further sustained by activation of p21 and NF-κB. Analysing the transcriptional regulation of DNA repair factors upon TMZ exposure, we found a strong repression of the mismatch repair (MMR) proteins MSH2, MSH6 and EXO1 as well as of Rad51, the central component of the homologous recombination pathway. The repression of these genes was regulated by the disruption of the E2F1/DP1 complex and is a specific trait of TMZ-induced senescent cells.ConclusionRepression of DNA repair in senescent cells may result in acquired drug resistance to TMZ and could render these cells susceptible to the accumulation of additional genomic alterations induced by anticancer therapy. In case of an escape from senescence, these genetically altered cells could contribute to increased aggressiveness and therapy resistance in a recurring tumour.
doi_str_mv 10.1136/esmoopen-2018-EACR25.245
format article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1136_esmoopen_2018_EACR25_245</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S205970292030243X</els_id><sourcerecordid>S205970292030243X</sourcerecordid><originalsourceid>FETCH-LOGICAL-b2575-539b778b60ed9cfe0d917f68f6eb78c9f6c1ce807b4d69cb44b6ec4cd87066093</originalsourceid><addsrcrecordid>eNqNkE1OwzAQhSMEElXpHXyBFDtN7GQZSvmRKooQrC17PGld5U92CuqODRflJCQKSCy7mtHMvPdGXxAQRueMLfg1-qppWqzDiLI0XOXLlyiZR3FyFkwimmShoFF2_q-_DGbe7ymlTMT9kE8C_7wJI0a_P7_yurOgakBHjDtsQ1ubA6AhHmv0gP2C2JpsS9voUvmuqRQBLEtPrCfK-was6vrzD9vtCOxUvUU_CG6fcuKwVdYRUK0C2x2vgotClR5nv3UavN2tXpcP4Xpz_7jM16GOEpGEySLTQqSaUzQZFEhNxkTB04KjFilkBQcGmFKhY8Mz0HGsOUIMJhWUc5otpkE6-oJrvHdYyNbZSrmjZFQO_OQfPznwkyM_2fPrpTejFPv_3i066cEODIx1CJ00jT3FZDGa6Gp_evQPfACQFg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>PO-210 Anticancer drug-induced senescence in glioblastoma cells is associated with changes in DNA repair capacity</title><source>Open Access: PubMed Central</source><source>ScienceDirect Journals (Raytheon)</source><creator>Christmann, M ; Aasland, D ; Roos, W ; Kaina, B ; Tomicic, M</creator><creatorcontrib>Christmann, M ; Aasland, D ; Roos, W ; Kaina, B ; Tomicic, M</creatorcontrib><description>IntroductionDespite extensive research, malignant glioma remains the most aggressive and fatal type of brain tumour. Following resection, therapy is based on radiation concomitant with the methylating agent temozolomide (TMZ), followed by adjuvant high dose TMZ treatment. The success of glioma therapy depends largely on the DNA repair capacity of the tumour cells, notable repair by MGMT, which confers resistance to TMZ. Beside DNA repair, other mechanisms involved in tumour protection may also play a role. These include the induction of a transient cell cycle arrest that provides time for repair and the induction of an irreversible cell cycle arrest in the form of senescence.Material and methodsMZ-induced senescence and repression of DNA repair was analysed in LN229, U87, LN308 and U138 glioblastoma cells using different techniques, including immunodetection, RT-qPCR, ChIP, Co-immunoprecipitation, ELISA, ß-Gal staining, C12FDG staining, AnexinV/PI staining, flow cytometry, pharmacological inhibition and si-RNA mediated knockdown.Results and discussionsWe show that following single and chronic TMZ exposure most glioma cells evade apoptosis and enter a senescent state. TMZ-induced senescence occurs in the G2/M phase of the cell cycle and is initiated by the ATR/CHK1-mediated degradation of CDC25c. It is further sustained by activation of p21 and NF-κB. Analysing the transcriptional regulation of DNA repair factors upon TMZ exposure, we found a strong repression of the mismatch repair (MMR) proteins MSH2, MSH6 and EXO1 as well as of Rad51, the central component of the homologous recombination pathway. The repression of these genes was regulated by the disruption of the E2F1/DP1 complex and is a specific trait of TMZ-induced senescent cells.ConclusionRepression of DNA repair in senescent cells may result in acquired drug resistance to TMZ and could render these cells susceptible to the accumulation of additional genomic alterations induced by anticancer therapy. In case of an escape from senescence, these genetically altered cells could contribute to increased aggressiveness and therapy resistance in a recurring tumour.</description><identifier>ISSN: 2059-7029</identifier><identifier>EISSN: 2059-7029</identifier><identifier>DOI: 10.1136/esmoopen-2018-EACR25.245</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>ESMO open, 2018-07, Vol.3 (Suppl 2), p.A102-A102</ispartof><rights>2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2018 © 2018 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b2575-539b778b60ed9cfe0d917f68f6eb78c9f6c1ce807b4d69cb44b6ec4cd87066093</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S205970292030243X$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,3536,27905,27906,45761</link.rule.ids></links><search><creatorcontrib>Christmann, M</creatorcontrib><creatorcontrib>Aasland, D</creatorcontrib><creatorcontrib>Roos, W</creatorcontrib><creatorcontrib>Kaina, B</creatorcontrib><creatorcontrib>Tomicic, M</creatorcontrib><title>PO-210 Anticancer drug-induced senescence in glioblastoma cells is associated with changes in DNA repair capacity</title><title>ESMO open</title><description>IntroductionDespite extensive research, malignant glioma remains the most aggressive and fatal type of brain tumour. Following resection, therapy is based on radiation concomitant with the methylating agent temozolomide (TMZ), followed by adjuvant high dose TMZ treatment. The success of glioma therapy depends largely on the DNA repair capacity of the tumour cells, notable repair by MGMT, which confers resistance to TMZ. Beside DNA repair, other mechanisms involved in tumour protection may also play a role. These include the induction of a transient cell cycle arrest that provides time for repair and the induction of an irreversible cell cycle arrest in the form of senescence.Material and methodsMZ-induced senescence and repression of DNA repair was analysed in LN229, U87, LN308 and U138 glioblastoma cells using different techniques, including immunodetection, RT-qPCR, ChIP, Co-immunoprecipitation, ELISA, ß-Gal staining, C12FDG staining, AnexinV/PI staining, flow cytometry, pharmacological inhibition and si-RNA mediated knockdown.Results and discussionsWe show that following single and chronic TMZ exposure most glioma cells evade apoptosis and enter a senescent state. TMZ-induced senescence occurs in the G2/M phase of the cell cycle and is initiated by the ATR/CHK1-mediated degradation of CDC25c. It is further sustained by activation of p21 and NF-κB. Analysing the transcriptional regulation of DNA repair factors upon TMZ exposure, we found a strong repression of the mismatch repair (MMR) proteins MSH2, MSH6 and EXO1 as well as of Rad51, the central component of the homologous recombination pathway. The repression of these genes was regulated by the disruption of the E2F1/DP1 complex and is a specific trait of TMZ-induced senescent cells.ConclusionRepression of DNA repair in senescent cells may result in acquired drug resistance to TMZ and could render these cells susceptible to the accumulation of additional genomic alterations induced by anticancer therapy. In case of an escape from senescence, these genetically altered cells could contribute to increased aggressiveness and therapy resistance in a recurring tumour.</description><issn>2059-7029</issn><issn>2059-7029</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><recordid>eNqNkE1OwzAQhSMEElXpHXyBFDtN7GQZSvmRKooQrC17PGld5U92CuqODRflJCQKSCy7mtHMvPdGXxAQRueMLfg1-qppWqzDiLI0XOXLlyiZR3FyFkwimmShoFF2_q-_DGbe7ymlTMT9kE8C_7wJI0a_P7_yurOgakBHjDtsQ1ubA6AhHmv0gP2C2JpsS9voUvmuqRQBLEtPrCfK-was6vrzD9vtCOxUvUU_CG6fcuKwVdYRUK0C2x2vgotClR5nv3UavN2tXpcP4Xpz_7jM16GOEpGEySLTQqSaUzQZFEhNxkTB04KjFilkBQcGmFKhY8Mz0HGsOUIMJhWUc5otpkE6-oJrvHdYyNbZSrmjZFQO_OQfPznwkyM_2fPrpTejFPv_3i066cEODIx1CJ00jT3FZDGa6Gp_evQPfACQFg</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Christmann, M</creator><creator>Aasland, D</creator><creator>Roos, W</creator><creator>Kaina, B</creator><creator>Tomicic, M</creator><general>Elsevier Ltd</general><scope>9YT</scope><scope>ACMMV</scope><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201807</creationdate><title>PO-210 Anticancer drug-induced senescence in glioblastoma cells is associated with changes in DNA repair capacity</title><author>Christmann, M ; Aasland, D ; Roos, W ; Kaina, B ; Tomicic, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b2575-539b778b60ed9cfe0d917f68f6eb78c9f6c1ce807b4d69cb44b6ec4cd87066093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Christmann, M</creatorcontrib><creatorcontrib>Aasland, D</creatorcontrib><creatorcontrib>Roos, W</creatorcontrib><creatorcontrib>Kaina, B</creatorcontrib><creatorcontrib>Tomicic, M</creatorcontrib><collection>BMJ Journals (Open Access)</collection><collection>BMJ Journals:Open Access</collection><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>ESMO open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Christmann, M</au><au>Aasland, D</au><au>Roos, W</au><au>Kaina, B</au><au>Tomicic, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PO-210 Anticancer drug-induced senescence in glioblastoma cells is associated with changes in DNA repair capacity</atitle><jtitle>ESMO open</jtitle><date>2018-07</date><risdate>2018</risdate><volume>3</volume><issue>Suppl 2</issue><spage>A102</spage><epage>A102</epage><pages>A102-A102</pages><issn>2059-7029</issn><eissn>2059-7029</eissn><abstract>IntroductionDespite extensive research, malignant glioma remains the most aggressive and fatal type of brain tumour. Following resection, therapy is based on radiation concomitant with the methylating agent temozolomide (TMZ), followed by adjuvant high dose TMZ treatment. The success of glioma therapy depends largely on the DNA repair capacity of the tumour cells, notable repair by MGMT, which confers resistance to TMZ. Beside DNA repair, other mechanisms involved in tumour protection may also play a role. These include the induction of a transient cell cycle arrest that provides time for repair and the induction of an irreversible cell cycle arrest in the form of senescence.Material and methodsMZ-induced senescence and repression of DNA repair was analysed in LN229, U87, LN308 and U138 glioblastoma cells using different techniques, including immunodetection, RT-qPCR, ChIP, Co-immunoprecipitation, ELISA, ß-Gal staining, C12FDG staining, AnexinV/PI staining, flow cytometry, pharmacological inhibition and si-RNA mediated knockdown.Results and discussionsWe show that following single and chronic TMZ exposure most glioma cells evade apoptosis and enter a senescent state. TMZ-induced senescence occurs in the G2/M phase of the cell cycle and is initiated by the ATR/CHK1-mediated degradation of CDC25c. It is further sustained by activation of p21 and NF-κB. Analysing the transcriptional regulation of DNA repair factors upon TMZ exposure, we found a strong repression of the mismatch repair (MMR) proteins MSH2, MSH6 and EXO1 as well as of Rad51, the central component of the homologous recombination pathway. The repression of these genes was regulated by the disruption of the E2F1/DP1 complex and is a specific trait of TMZ-induced senescent cells.ConclusionRepression of DNA repair in senescent cells may result in acquired drug resistance to TMZ and could render these cells susceptible to the accumulation of additional genomic alterations induced by anticancer therapy. In case of an escape from senescence, these genetically altered cells could contribute to increased aggressiveness and therapy resistance in a recurring tumour.</abstract><pub>Elsevier Ltd</pub><doi>10.1136/esmoopen-2018-EACR25.245</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2059-7029
ispartof ESMO open, 2018-07, Vol.3 (Suppl 2), p.A102-A102
issn 2059-7029
2059-7029
language eng
recordid cdi_crossref_primary_10_1136_esmoopen_2018_EACR25_245
source Open Access: PubMed Central; ScienceDirect Journals (Raytheon)
title PO-210 Anticancer drug-induced senescence in glioblastoma cells is associated with changes in DNA repair capacity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T17%3A15%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PO-210%E2%80%85Anticancer%20drug-induced%20senescence%20in%20glioblastoma%20cells%20is%20associated%20with%20changes%20in%20DNA%20repair%20capacity&rft.jtitle=ESMO%20open&rft.au=Christmann,%20M&rft.date=2018-07&rft.volume=3&rft.issue=Suppl%202&rft.spage=A102&rft.epage=A102&rft.pages=A102-A102&rft.issn=2059-7029&rft.eissn=2059-7029&rft_id=info:doi/10.1136/esmoopen-2018-EACR25.245&rft_dat=%3Celsevier_cross%3ES205970292030243X%3C/elsevier_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b2575-539b778b60ed9cfe0d917f68f6eb78c9f6c1ce807b4d69cb44b6ec4cd87066093%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true